Celgene stock: buy or sell?

CELG stock price: $95.71 0.03% At close on August 22nd, 2019

Updated on:
August 22nd, 2019

3

Celgene ended today at $95.71 and remained constant a neutral 0.03%. Counting Thursday, it's been 5 climbing sessions in a row, gaining $2.40 or 2.58%.

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide.

Should I buy Celgene stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best moment to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

None of our preferred buy setups matches with Celgene stock situation right now, hence this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Celgene stock a buy?

Financial institutions and banks post stock ratings everyday. At Stocks2.com, we collected 15 ratings published for CELG stock in the last month.

Is CELG a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-19MizuhoBuyNeutral
2019-7-30Cowenn/aHold
2019-7-3Mizuhon/aBuy
2019-6-25Mizuhon/aBuy
2019-5-3BarclaysOverweightEqual Weight
2019-4-5Mizuhon/aBuy
2019-4-5Cantor FitzgeraldOverweightNeutral
2019-4-1William BlairOutperformMarket Perform
2019-4-1UBS GroupBuyNeutral
2019-4-1Sanford C. BernsteinOutperformMarket Perform
2019-4-1Atlantic SecuritiesOverweightNeutral
2019-2-26Cowenn/aMarket Perform
2019-2-1Jefferies Financial GroupBuyHold
2019-1-4Robert W. BairdNeutralOutperform
2019-1-3Wells Fargo & Con/aHold

Celgene stock analysis

Daily outlook

Celgene shares remained stable 0.03% to $95.71 today.

Shares of Celgene closed today at $95.71 and remained stable a neutral 0.03%. CELG shows a strong short term uptrend with several rising tops and rising bottoms. Since its last bottom on August 15th, CELG climbed unceasignly breaking out above its last top at 95.59. Since April when SMA100d and SMA200d crossed up, CELG price gained $2.04 per share (2.18%). Since Friday when CELG stock price broke up the SMA100d line, it gained $2.40 (2.57%).

CELG stock chart (daily)

Weekly outlook

Shares of Celgene closed this week at $95.71 and appreciated a slightly good 1.02%.

The downtrend marked by CELG has left consecutive falling peaks and bottoms. There is a chance to rebound and reverse this situation if price can hold above the level. Since SMA20d and SMA40w crossed up by mid April, CELG price climbed $1.57 per share (1.67%). Since late December 2018 when CELG stock price broke up the SMA40w line, it gained $33.28 (53.31%).

CELG stock chart (weekly)

Celgene stock price history

Celgene stock went public on July 28th, 1987 with a price of $0.481. Since then, CELG stock grew a 19,839.60%, with an average of 620.00% per year. If you had invested right after CELG's IPO a $1,000 in Celgene stock in 1987, it would worth $198,396.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Celgene stock historical price chart

CELG stock reached 52-week highs on June at $98.97, and all-time highs 2017-10-02 with a price of 147.17.

Celgene stock price target is $101.40

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. We detected 7 price forecasts for Celgene stock released in the last 30 days:
CELG stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-7-30CowenReiteratesn/a$102.00-
2019-7-3MizuhoReiteratesn/a$103.00-
2019-6-25MizuhoReiteratesn/a$103.00-
2019-5-3BarclaysDowngradesn/a$102.00-
2019-4-5MizuhoSet Price Targetn/a$103.00-
2019-2-26CowenInitiatesn/a$102.00-
2019-2-1Jefferies Financial GroupDowngradesn/a$95.00-
(in average)$0.00$101.400.0%
The price prediction for Celgene stock is $101.40, moving in a range between $103.00 and $95.00. In average, analysts' outlook on CELG price forecast is stable from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

Since May, when Celgene presented its last earnings report, it remained steady a neutral 0.73%. Unfortunately, reported EPS is not yet available in our database.
CELG earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q2-n/a2.58n/a
2017-Q32017-10-261.871.912.1%
2017-Q42018-01-251.9721.5%
2018-Q12018-05-041.781.61-9.6%
2018-Q22018-07-261.861.860.0%
2018-Q32018-10-252.022.030.5%
2018-Q42019-01-312.122.23.8%
2019-Q12019-05-022.51n/an/a
2019-Q2-n/an/an/a
2019-Q3-n/an/an/a

Annual financial results

Compared to 2017, last anual turnover report draw a super good increase of 17.52% to $15,281.00 million USD. However, its earnings margin (compared to sales) raised to 26.48%, that is $4,046.00 million.

To have an up to date picture of the financial situation of Celgene, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2019-Q1 that can be compared to 2018 fiscal year results. Annual Celgene TTM sales up to March 2019 were $15,768.00 and income was $4,745.00 million dollars. If we compare this TTM figures with the last reported annuality, we can review Celgene business evolution since December 2018: Annual turnover up to March, compared to lastest yearly report, gained a decent 3.19%. In line, profit margin (net income/sales) stepped up at 26.48%.

CELG annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$6,480 M-$1,450 M22.4%-
2014$7,670 M18.37%$2,000 M26.1%37.92%
2015$9,256 M20.67%$1,602 M17.3%-19.90%
2016$11,229 M21.32%$1,999 M17.8%24.79%
2017$13,003 M15.80%$2,940 M22.6%47.06%
2018$15,281 M17.52%$4,046 M26.5%37.62%
TTM $15,768 M3.19%$4,745 M30.1%17.28%

Quarterly financial results

Celgene reported $4,025.00 million in sales for 2019-Q1, a -0.30% decline compared to previous quarter. Reported quarter income marked $1,545.00 million with a profit margin of 38.39%. Profit margin skyrocketed a 11.81% compared to previous quarter when profit margin was 26.58%. When comparing revenues to same quarter last year, Celgene sales marked an extraordinary increase and boosted a 13.76%.
CELG quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q2$3,190 M-$1,060 M33.2%-
2017-Q3$3,280 M2.82%$988 M30.1%-6.79%
2017-Q4$3,483 M6.19%$-81 M-2.3%-108.20%
2018-Q1$3,538 M1.58%$846 M23.9%-1,144.44%
2018-Q2$3,814 M7.80%$1,045 M27.4%23.52%
2018-Q3$3,892 M2.05%$1,082 M27.8%3.54%
2018-Q4$4,037 M3.73%$1,073 M26.6%-0.83%
2019-Q1$4,025 M-0.30%$1,545 M38.4%43.99%

Celgene ownership

When you are planning to buy shares of a stock, it's always worth to have a look its ownership structure.

Celgene shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.22% of all shares.

In case of Celgene stock, 77.62% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for CELG stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Celgene:

CELGALXNAMGNBIIBEPZM
Market cap$67.1 B$25.8 B$124.1 B$45.2 B$943.5 M
Total shares701.0 M224.3 M609.9 M193.9 M69.5 M
Float shares706.3 M223.6 M598.3 M184.0 M76.3 M
  - Institutional holdings (%)77.6%96.8%81.9%93.4%93.2%
  - Insider holdings (%)0.2%0.3%0.2%0.5%4.9%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

Celgene summary

Thursday, August 22nd, 2019
Open$95.75
Close$95.71
Day range$95.16 - $95.99
Previous close$95.68
Session gain0.03%
Average true range$1.13
50d mov avg$93.65
100d mov avg$94.25
200d mov avg$87.36
Daily patternlb03c
Weekly pattern lt02a

Celgene performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We chose Alexion Pharmaceuticals, Amgen, Biogen, Epizyme, Gilead Sciences, Illumina, , Eli Lilly and and Acceleron Pharma as the bechmarking frame for Celgene stock.
Stock3m6m12m
CELGCelgene0.49%7.37%6.43%
ALXNAlexion Pharmaceu...-9.60%-11.48%-2.26%
AMGNAmgen19.60%10.20%6.63%
BIIBBiogen2.70%-28.33%-31.88%
EPZMEpizyme5.03%14.60%17.07%
GILDGilead Sciences-3.08%-0.43%-9.60%
ILMNIllumina-7.64%-4.15%-15.27%
JNJ-5.27%-2.41%-0.66%
LLYEli Lilly and-4.03%-9.10%7.68%
XLRNAcceleron Pharma12.53%10.74%-5.00%

Celgene competitors

We chose a few stocks to conform a list of Celgene competitors to check if you are interested in investing in CELG:

Latest Celgene stock news